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Abstract
STAT2 is the quintessential transcription factor for type 1 interferons (IFNs), where it func-
tions as a heterodimer with STAT1. However, the human and murine STAT2-deficient phe-
notypes suggest important additional and currently unidentified type 1 IFN-independent
activities. Here, we show that STAT2 constitutively bound to STAT1, but not STAT3, via a
conserved interface. While this interaction was irrelevant for type 1 interferon signaling and
STAT1 activation, it precluded the nuclear translocation specifically of STAT1 in response
to IFN-γ, interleukin-6 (IL-6), and IL-27. This is explained by the dimerization between acti-
vated STAT1 and unphosphorylated STAT2, whereby the semiphosphorylated dimers
adopted a conformation incapable of importin-α binding. This, in turn, substantially attenu-
ated cardinal IFN-γ responses, including MHC expression, senescence, and antiparasitic
immunity, and shifted the transcriptional output of IL-27 from STAT1 to STAT3. Our results
uncover STAT2 as a pervasive cytokine regulator due to its inhibition of STAT1 in multiple
signaling pathways and provide an understanding of the type 1 interferon-independent
activities of this protein.
Author Summary
For more than a quarter century, we have known that STAT1 and STAT2 are essential for
the classic host immune defense system against viral infections known as the type 1 inter-
feron response. While STAT1 has since been assignedmultiple additional roles, STAT2 is
thought to function exclusively as the principal partner of STAT1 in the type 1 interferon
system. However, patients and animals that are deficient in STAT2 show a surprisingly
varied and sometimes subtle phenotype not fully accounted for by the known functions of
this protein. Our investigations reveal an entirely novel facet of STAT2 action, namely as
an innate inhibitor of STAT1 in its multiple biological roles. We identify the molecular
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mechanism of STAT1 inhibition and generate a novel biological tool with which we can
dissociate STAT2’s activating and inhibitory effects on STAT1. We use this tool to show
that STAT2 has major roles beyond antiviral protection, for example, in regulating cell
proliferation and immune cell functions, as well as in killing intracellular parasites. These
findings considerably expand our knowledge of STAT2 biology and necessitate a reassess-
ment of regulatorymechanisms central to innate immunity and the therapeutic use of
interferons.
Introduction
Cytokines are a structurally and functionally diverse group of small proteins that function as
extracellular signalingmolecules. They control all aspects of immune cell biology including
development, differentiation, activation, and death and orchestrate the functioning of the
entire immune system. Studies of patients and animals that lack cytokines or their receptors
have assigned distinct activities to individual cytokines, while simultaneously revealing a more
complex scenario with extensive functional overlap [1]. The molecular understanding of how
the balance is struck between specificity and redundancy is incomplete and a central problem
in cytokine biology. This is because there are over 50 different cytokines but only seven signal
transducer and activator of transcription (STAT) proteins that deliver the signals, namely
STAT1-4, 5A, 5B, and 6 [2]. A cytokine binding to its receptor triggers a phosphorylation cas-
cade resulting in the modification of STAT proteins at a single tyrosine residue, an event also
called STAT activation [3]. STAT activation is associated with the rearrangement of preformed
dimers from an antiparallel conformation to a parallel conformation, whereby interactions
between the aminoterminal domains (N domains) are critically important [4,5]. Transition to
the parallel conformation has important consequences; transforming the STATs into
sequence-specific transcription factors that can bind DNA with high affinity [6]. Moreover,
and contrary to the antiparallel dimers, which are carrier-independent nucleocytoplasmic shut-
tling proteins, activated dimers require transport factors termed importins for nuclear translo-
cation and accumulation [7]. STAT1 is the major STAT protein activated in response to IFN-γ,
the sole type 2 IFN [3]. STAT1 mediates many of the IFN-γ functions through the direct activa-
tion of genes such as those that are essential for host defense against intracellular bacteria and
parasites [8]. Given the self-damaging potential of these activities, IFN-γ signaling requires
tight control, such as feedback inhibition of Janus kinases (JAKs) through the up-regulation of
suppressor of cytokine signalling (SOCS) proteins [9]. STAT1 is activated by multiple cyto-
kines in addition to IFN-γ, including interleukin-27 and -6 (IL-27 and IL-6), and often in con-
junction with the closely related STAT3 [10]. STAT1 and STAT3 have very similar DNA
sequence preferences, yet their transcriptomes are distinct and overlap only partially [11,12].
In fact, STAT1 and STAT3 oppose each other in many biological processes, but little is known
about mechanisms that determine their relative contributions to the overall transcription
output.
In contrast to STAT1 and STAT3, which take part in multiple signaling pathways, STAT2 is
considered to be involved in only a single intracellular pathway, which emanates from the
receptors of type 1 and type 3 IFNs [13]. In further contrast to the other STAT proteins, which
primarily assemble homodimers upon cytokine stimulation, STAT2 exclusively forms hetero-
dimers with concurrently activated STAT1, which associate with another DNA-binding pro-
tein, IRF9, and form the transcription factor interferon-stimulated gene factor 3 (ISGF3) [3].
STAT2 deficiency in both patients and animals accordingly precludes the up-regulation of
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hundreds of genes in response to IFN-α or IFN-β and the other type 1/3 IFNs, many of which
have direct and indirect antiviral activity, and results in a marked susceptibility to viral infec-
tions [14,15]. Other aspects of STAT2 deficiency are unexplained, though, such as the exacer-
bation of experimental sepsis observedwith STAT2-deficient mice, given that genetic deletion
of other components of type 1 IFN signaling results in the opposite phenotype, namely protec-
tion against sepsis [16,17]. These, and other, data suggest additional roles for STAT2 in cyto-
kine signaling beyond ISGF3 and type 1/3 IFNs. In this context, we now report that STAT2 is a
critical regulator for multiple STAT1-activating cytokines.We provide detailed insight into the
molecular underpinnings, and examine the consequences for key cytokine activities both in
vitro and in vivo. Our experiments showed that STAT2 attenuated crucial immunomodulatory
and antimicrobial effector functions of IFN-γ; and in IL-27-mediated transcription, STAT2
shifted the balance away from STAT1 to STAT3. Thus, in addition to its well-known role as an
IFN-activated transcription factor, STAT2 has pervasive activation-independent activities as a
STAT1 negative regulator in multiple signaling pathways.
Results
STAT2 Binds to STAT1 through Exceptionally Strong N Domain
Interactions
During studies of STAT protein self-association,we noticed a more prominent cytoplasmic
steady-state localization of STAT1 in cells that expressed STAT2 compared to cells that lacked
it (Fig 1A). This observationwas recapitulated in cells overexpressing STAT1 and STAT2
tagged with cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP), respectively.
The tagged STAT1 distributed throughout the cell (Fig 1B, panels 1–4), while separately
expressed STAT2 accumulated in the cytoplasm (Fig 1B, panels 5 and 6). Coexpression of
STAT1 and STAT2 demonstrated the cytoplasmic redistribution of STAT1 (Fig 1B, panels 7
and 8). A similar redistribution upon STAT2 overexpression was not observedwith the two
STAT proteins most closely related to STAT1, STAT3 and STAT4 (S1 Fig). The results sug-
gested binding interactions specifically between STAT1 and STAT2. Both are nucleocytoplas-
mic shuttling proteins, whereby STAT2 accumulates in the cytoplasm due to efficient nuclear
export signal (NES)-mediated transport by the transportin CRM1 [18,19]. In line with this rea-
soning, inactivation of the STAT2 NES, either by genetic removal of the NES-containing C ter-
minal transactivation domain or by chemical inhibition of the NES receptor protein CRM1
[20], resulted in similar pancellular distribution of both STAT2 and STAT1 (S2 Fig). We then
asked whethermutational inactivation of the interface that mediates the homodimerization of
unphosphorylated (aka latent) STAT1, namely replacement with alanine of phenylalanine 77
in the N domain [21], affected its colocalizationwith STAT2. This was the case, as the mutant
STAT1 failed to colocalizewith STAT2 (Fig 1B, panels 9 and 10). We then did the reverse
experiment, i.e., we coexpressedwild type (WT) STAT1 and mutant STAT2 that harbored ala-
nine in the STAT1 F77 homologous position leucine 82 (Fig 1B, panels 11 and 12) or the func-
tionally equivalent double mutation LL81,82AA (S3 Fig). Strikingly, the two STAT2 mutants
phenocopied STAT1-F77A. The mutated STAT2 retained cytoplasmic accumulation, but
STAT1 failed to redistribute.We concluded that STAT1 homodimers and its heterodimers
with STAT2 assembled via identical N domain-mediated interactions.
Quantitative data on the heterodimerization of STAT proteins or their N domains were not
previously available. Data for homodimers demonstrate that STAT N domains differ consider-
ably in their interaction strengths, and that this measure can be used as a proxy for dimeriza-
tion of the full-length STAT proteins [5,22]. We therefore purifiedN domains of STAT1 and
STAT2 and determined dissociation constants for homo- and heterodimers using analytical
STAT2 Regulation of Cytokine Signals
PLOS Biology | DOI:10.1371/journal.pbio.2000117 October 25, 2016 3 / 27
Fig 1. STAT2 binds STAT1 via high affinity N Domain interactions. (A) Stat2-deficient human U6A cells (S2-/-) and parental 2fTGH cells (WT) were
fixed and processed for immunostaining using STAT1 antibody, nuclear counterstaining was with DAPI. Shown are deconvolution fluorescence
micrographs. The corresponding bar graphs show STAT1 cytoplasmic/nuclear signal ratios and standard deviation (s.d.) produced using line scanning to
acquire mean fluorescence intensities (MeFIs) in cytoplasm and nucleus. Scale bar = 15 μm. (B) STAT1-CFP and STAT2-YFP variants were singly or
coexpressed in HeLa cells and their localization was determined by deconvolution fluorescence microscopy. Bar graphs show cytoplasmic/nuclear signal
ratios for STAT1 (black bars) and STAT2 (white bar) acquired as described in (A). Scale bar = 15 μm. (C) Equilibration sedimentation analyses of homo-
and heterotypic associations of STAT1 and STAT2 recombinant N domains. Equilibrium dissociation constant (KD); (STAT2-mut) STAT2 LL81,82AA. See
S1 Data for raw data.
doi:10.1371/journal.pbio.2000117.g001
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ultracentrifugation (Fig 1C). STAT2 homodimers were found to associate at high micromolar
concentrations, indicating weak protein interactions (Fig 1C). For comparison, homodimers of
STAT1 N domain were about 50-fold stronger (Fig 1C), in agreement with previous measure-
ments [22]. A very different picture emerged when STAT2 heterodimerizationwas assessed.
Heterodimerization between STAT2 and STAT1 was exceptional, namely at least 1,000 times
stronger than STAT1 homodimers. In sharp contrast, the LL81,82AA-mutated STAT2 N
domain that abrogated colocalizationwith STAT1 in living cells was essentially devoid of
dimerization activity at the concentrations tested (Fig 1C). These experiments confirmed that
identical N domain interactions stabilized the homodimers and heterodimers of STAT1,
whereby the heterotypic interactions were stronger by at least three orders of magnitude.
Latent STAT2 Inhibits the IFN-γ-Induced Nuclear Import and DNA
Binding of STAT1
Next, we evaluated the effects of STAT2 on the IFN-dependent functions of STAT1. Western
blotting experiments using cell extracts from control and STAT2-overexpressing HeLa cells
confirmed that IFN-γ induced the tyrosine phosphorylation of STAT1, but not STAT2, (Fig
2A, lanes 3, 4, 9, and 10), whereas IFN-β activated both STATs (Fig 2A, lanes 5, 6, 11, and 12).
STAT2 overexpression, however, was without negative consequences for STAT1 activation by
both IFN-γ (Fig 2A, lanes 3 and 4) and IFN-β (lanes 5 and 6). Yet, despite undiminished activa-
tion, the IFN-γ-induced nuclear translocation of STAT1 was significantly diminished in the
presence of STAT2 at native protein levels (Fig 2B). To explore the underlyingmolecular
mechanisms, we transiently expressed STAT2 variant proteins in HeLa cells and observed the
nuclear translocation of endogenous STAT1 in response to IFN-γ. Recombinant STAT2, like
the endogenous STAT2, inhibited STAT1 nuclear accumulation (Fig 2C, panels 1 and 2), in
agreement with a previous observation by Julkunen and colleagues [23]. The same result was
obtained with C-terminally truncated STAT2 (aa 1–702) lacking NES activity, demonstrating
that cytoplasmic retention of activated STAT1 is independent of STAT2 nuclear export (Fig
2C, panels 5 and 6). In stark contrast, the STAT2-L82A mutant that cannot bind to STAT1
failed to prevent the IFN-γ-induced nuclear translocation of activated STAT1 (Fig 2C, panels 3
and 4), thus recapitulating its effect on the latent STAT1 (Fig 1B, panels 11 and 12). STAT1
nuclear import in response to type 1 IFN, in contrast, was unaffected by disrupted STAT1:
STAT2 heterodimerization (S4A Fig).
Another major consequence of STAT1 activation is its ability to bind specificDNA
sequences with high affinity, namely to the interferon-stimulated response element (ISRE) as
part of ISGF3, and to the gamma interferon-activated site (GAS) as a homodimer (gamma
interferon-activated factor; GAF) [3]. To test whether STAT2 interferes with STAT1 DNA
binding, we used electrophoreticmobility shift assays (EMSAs) with extracts from STAT2-defi-
cient human U6A fibrosarcoma cells and stable derivatives expressingWT STAT2 or mutant
STAT2-L82A (Fig 2D, S5 Fig). Of note, whole cell extracts normalized for activated STAT1
were used to account for the nuclear import inhibition caused by STAT2. As shown in Fig 2D,
STAT2 was required for IFN-β-induced ISGF3 formation, wherebyWT STAT2 and the
STAT1-binding mutant were indistinguishable (lanes 4 and 6). In contrast, the IFN-γ-induced
STAT1 homodimer (GAF) activity expectedly did not require STAT2 (lane 8), yet a substantial
difference was observedbetween theWT and mutant STAT2-L82A-containing extracts.WT
STAT2 resulted in75% reduced GAF activity (lanes 8 and 10), whereas the mutant STAT2
left GAF essentially unchanged (lanes 8 and 12).
Since increasing the concentration of STAT2 strongly affected STAT1 activities, we deter-
mined their abundance (Fig 2E, S6 Fig). In all cell lines tested, the full-length STAT1α was
STAT2 Regulation of Cytokine Signals
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present in molar excess over STAT2, albeit to a considerably varying degree (2- to 25-fold).
As both STATs are IFN-stimulated genes (ISGs), prolonged treatment with a low IFN-γ con-
centration (priming) expectedly increased their concentration (Fig 2E) [24], whereby STA-
T1α’s excess over STAT2 was further heightened 2- to 5-fold. We concluded that a sizable and
dynamic STAT1 fractionwas bound to unphosphorylated STAT2 before IFN treatment. Since
STAT2 remained bound to STAT1 in response to IFN-γ, but was not phosphorylated, semi-
phosphorylated heterodimers resulted that precluded the subsequent nuclear import and DNA
binding of the activated STAT1.
STAT2 Inhibits the Nuclear Import Specifically of STAT1 in Multiple
Signaling Pathways
To examine if STAT2’s nuclear import inhibition was specific for STAT1 or IFN-γ signaling,
we treatedWT STAT2- and STAT2-L82A-reconstituted U6A cells with IL-6 or IL-27, two
cytokines that signal predominantly via STAT1 and STAT3. As shown in Fig 3A, IL-6 and IL-
27 activated both STAT1 (lanes 1–3 and 5–7) and STAT3 (lanes 17–19 and 21–23), whereas
IFN-γ activated predominantly STAT1 (lanes 4, 8, 20, 24). Moreover, the tyrosine phosphory-
lation of both STAT1 and STAT3 was indistinguishable in cells expressingWT STAT2 or its
STAT1-binding mutant. STAT2, on the other hand, remained unphosphorylated in response
to all three cytokines (lanes 9–16). We then observed the intracellular distribution of STAT1,
STAT2, and STAT3 with fluorescencemicroscopy before and after the treatment with IL-6 or
IL-27. In line with their lack of activation (Fig 3A), the two STAT2 variants showed unaltered
cytoplasmic accumulation under all conditions (Fig 3B; YFP-channel). Activated STAT1 and
STAT3 were detectable with their respective anti-phosphorylated tyrosine antibody in response
to IL-6 (middle panels) and IL-27 (bottom panels), which too agreed with the western blotting
results (Fig 3A). The activated STAT3 entered the nucleus in the presence of WT as well as
mutated STAT2 (Fig 3B, panels 14, 16, 22, and 24). The IL-27- and IL-6-activated STAT1, in
contrast, entered the nucleus in the presence of mutated STAT2 (panels 12, 20), but not WT
STAT2 (panels 10, 18), similar to the results with IFN-γ (Fig 2B). Thus, STAT2 nuclear import
inhibition was specific for STAT1 but not linked to a specific cytokine stimulus.
Semiphosphorylated STAT1:STAT2 Heterodimers Adopt Antiparallel
Conformation Incompatible with Importin-α5 Binding
Activated STAT1 homodimers require the parallel conformation for nuclear import and DNA
binding [6,21]. The respective requirements of the heterodimers were unknown. To
Fig 2. STAT2 inhibits nuclear translocation and DNA-binding of IFN-γ-activated STAT1. (A) Quantitative western
blotting with extracts from HeLa cells expressing STAT2-YFP or empty vector (ctrl). The positions of latent (α) and
activated (αp) STAT1 (S1) and STAT2 (S2) are indicated. Transfected (-YFP) and endogenous (-endog.) STAT2 are
discriminated. kD, kilo Dalton. Bar graph shows mean and s.d. (B) STAT2-deficient human U6A cells (S2-/-) and
parental 2fTGH cells (WT) were treated for 1 h with 1 U/ml IFN-γ, fixed and processed for immunostaining using anti-
phospho-Y701 STAT1 antibody, nuclear counterstaining was with DAPI. Shown are deconvolution fluorescence
micrographs. The corresponding bar graphs show activated STAT1 cytoplasmic/nuclear signal ratios and s.d. produced
using line scanning to acquire MeFIs in cytoplasm and the nucleus. Scale bar = 15 μm. (C) as (B), with HeLa cells
overexpressing WT STAT2-YFP or variants L82A and truncated STAT2 (ΔC) treated for 1 h with 50 U/ml IFN-γ. (*)
denotes cell nuclei. Bar graphs show cytoplasmic/nuclear signal ratios and s.d. for phospho-Y701 STAT1 in the
presence of the indicated STAT2 variants. Scale bar = 15 μm. (D) Electrophoretic mobility shift assays (EMSAs) with
radiolabeled interferon-stimulated response element (ISRE) (left) and gamma interferon-activated site (GAS) (right)
probes to detect ISGF3 and gamma interferon-activated factor (GAF), respectively, the positions of which and of the free
probes are indicated. Extracts from parental (S2-/-) and stably STAT2-reconstituted (S2 WT or S2 L82A) human U6A
cells were used. (E) Quantitative western blotting results with extracts from the indicated cell lines showing the positions
of STAT1 splice variants (αS1α/β) and STAT2 (αS2). Bar graph shows mean and s.d. See S1 Data for raw data.
doi:10.1371/journal.pbio.2000117.g002
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understand STAT2 functioning as an import inhibitor of activated STAT1, we performed
STAT2 coimmunoprecipitation assays with FLAG-taggedWT STAT1 and three STAT1
mutants deficient either in tyrosine phosphorylation (Y701F), or specifically antiparallel
dimerization (F77A), or both (F77A, Y701F), to infer the conformation of unphosphorylated,
semiphosphorylated, and fully phosphorylated STAT1:STAT2 heterodimers in vivo (Fig 4A).
In cell extracts from IFN-untreated cells (Fig 4A, lanes 1–10), STAT2 coprecipitated withWT
STAT1 and STAT1-Y701F (lanes 2, 4), but not STAT1-F77A and the STAT1-F77A, Y701F
double mutant (lanes 3, 5). Thus, unphosphorylated STAT1 heterodimers, like the homodi-
mers, required N domain interactions. To examine heterodimerization of the phosphorylated
Fig 3. STAT2 inhibits specifically STAT1 in response to both IL-27 and IL-6. (A) Western blot indicating the positions of latent
(α) and activated (αp) STAT1α/β (S1α/β), STAT2 (S2), and STAT3 (S3). STAT2-YFP (S2-YFP) and its YFP-free degradation
product (*) are discriminated. Treatment of cells was without or with IFN-γ, IL-27, or combined IL-6 and soluble IL-6 receptor (IL-6/
IL-6R). (B) Deconvolution microscopy detecting activated STAT1 (anti-phospho-Y701 STAT1 antibody) and STAT3 (anti-
phospho-Y705 STAT3 antibody) in STAT2-YFP-reconstituted U6A cells left untreated (top) or cotreated with IL-6/soluble IL-6
receptor (middle) or with IL-27 (bottom). (*) denotes cell nuclei. Scale bar = 15 μm.
doi:10.1371/journal.pbio.2000117.g003
STAT2 Regulation of Cytokine Signals
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STATs, we repeated the experiment with extracts from IFN-β-treated cells (Fig 4A, lanes 11–
20). In this experiment, IFN-βwas used rather than IFN-γ in order to generate fully tyrosine-
phosphorylated heterodimers as the positive control. As expected, the tyrosine-phosphorylated
STAT2 coprecipitated with tyrosine-phosphorylatedWT STAT1 (lane 12). Moreover, but con-
trary to the unphosphorylated situation (lane 3), tyrosine-phosphorylated STAT2 coprecipi-
tated similarly well with the activated STAT1-F77A dimerizationmutant (lane 13),
presumably throughmutual src kinase homology 2 (SH2):phosphotyrosine interactions. Het-
erodimerization also occurred if one partner was unphosphorylated (STAT1-Y701F) (lane 14),
but not if the double mutant STAT1-F77A, Y701F with additionally disrupted N domain inter-
actions was used (lane 15). We therefore inferred that N domains—but not single SH2:phos-
photyrosine interactions—sustained semiphosphorylated heterodimers, supportive of an
antiparallel conformation. Fully phosphorylated STAT dimers enter the nucleus bound to
importin-α5 [25,26]. To compare importin binding of the semiphosphorylated variant, WT
STAT1 or the nonphosphorylatable STAT1-Y701F (both YFP-tagged) were coexpressedwith
FLAG-tagged importin-α5, and STAT activation was induced by IFN-β treatment as before
(Fig 4B). It should be noted that although experimental IFN-β-induced semiphosphorylated
heterodimers (Y701F-STAT1:STAT2 -P) and their natural IFN-γ-induced counterparts
(P-STAT1:STAT2-U) are not identical, they are both defective in carrier-mediated nuclear
import [27], which suggests that they can be used interchangeably to study importin binding.
As shown in Fig 4B, importin-α5 coprecipitated with both endogenous and heterologous
STAT1 and STAT2, but only in extracts from IFN-β-treated cells (lanes 1 and 2 for STAT1;
and 7 and 8 for STAT2), which agrees with the requirement of STAT activation for importin-
α5 binding [24].
Semiphosphorylated STAT dimers, in contrast, did not bind importin-α5, as demonstrated
by the lack of STAT1-Y701F coprecipitation with importin-α5 (lane 4), despite abundant
phosphorylated STAT2 in the extract (lane 22). These results predicted that acquisition of
IFN-γ responsiveness by STAT2 abrogated its inhibition of STAT1 nuclear import. This was
tested by swapping the SH2 domain from STAT1 into STAT2, which led to the IFN-γ-induc-
ible tyrosine phosphorylation of the hybrid STAT2 reported by Darnell’s group [28]. Before
IFN treatment, the hybrid STAT2, likeWT, accumulated in the cytoplasm together with
STAT1 (Fig 4C, panels 1 and 2). Unlike WT STAT2, but as predicted, hybrid STAT2 did not
inhibit the nuclear import of activated STAT1, which accumulated strongly in the nucleus
upon IFN-γ treatment (Fig 4C, panels 3 and 4). Restoration of IFN-γ unresponsiveness of
hybrid STAT2 by introducing the SH2 domain-inactivatingmutation R602L [29], on the other
hand, restored STAT1 inhibition (Fig 4C, panels 5 and 6). In conclusion, the inhibition of acti-
vated STAT1 required heterodimerization specificallywith unphosphorylated STAT2, because
Fig 4. Dimers between latent STAT2 and activated STAT1 adopt an antiparallel conformation
incompatible with importin-mediated nuclear import. (A, B) Immunoblots of precipitates (IP) and cell
extracts (input) from immunoprecipitation experiments using anti-FLAG beads and HEK 293T cell extracts.
Multicolor imaging results are shown, obtained by the concurrent application of up to three antibodies. (A)
Cells were cotransfected with STAT2 and FLAG-tagged STAT1 variants (WT; F77A, FA; Y701F, YF; double
mutant, FA-YF) or empty vector (ctrl) and left untreated (top) or treated with IFN-β (bottom). The positions of
FLAG-tag (αFLAG) and latent (α) and activated (αp) STAT1 (S1) and STAT2 (S2) are indicated. (B) Cells
were cotransfected with FLAG-tagged importin-α5 and YFP-tagged STAT1 (WT) or Y701F (YF) mutant or
empty vector (ctrl) and treated without or with IFN-β. Labelling performed as in (A). Transfected (-YFP) and
endogenous (-endog.) STATs are discriminated. Native YFP (free) and its STAT1 fusion (S1) were detected
with anti-GFP antibody. (*) cross-reacting IgG. Note coprecipitation of the endogenous STAT1 in lanes 2, 4,
and 6, i.e., with the IFN-β-treated extracts. (C) Schematic displaying STAT1, STAT2, and hybrid STAT2
structure accompanying widefield microscopy detecting the endogenous STAT1 (anti-STAT1 C terminus
antibody decorated with Cy3) in cells expressing YFP-tagged hybrid STAT2. (*) denotes cell nucleus. Scale
bar = 15 μm.
doi:10.1371/journal.pbio.2000117.g004
STAT2 Regulation of Cytokine Signals
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such dimers adopted an antiparallel conformation incompatible with binding DNA and impor-
tin-α5.
STAT2 Suppresses IFN-γ-Induced Gene Expression
We then evaluated the consequences for IFN-γ-induced gene transcription. STAT2 overex-
pression in HeLa cells resulted in significantly reduced STAT1 reporter gene activity (Fig 5A).
The mutant STAT2-L82A, in contrast, displayed significantly higher reporter gene activity (Fig
5A). To elucidate the role of STAT2 for the transcription of endogenous IFN-γ-regulated
genes, we used quantitative RT-PCR and immortalizedWT and STAT2-deficient mouse mac-
rophages, whereby a similar picture emerged. Aside from notable exceptions such as the IFN
negative feedback regulators Socs1 and Isg15, most IFN-γ-regulated genes tested showed signif-
icantly increased gene expression in the absence of STAT2, including CxCl9,CxCl10, Irf1, Ido1,
Fig 5. Role of IRF9 and STAT2:STAT1 heterodimerization for gene induction by IFN-γ and IFN-β. (A-D)
Gene expression results in response to IFN-γ. (A) STAT1-responsive (3xGAS) luciferase-reporter gene assay
with YFP-tagged WT STAT2 (WT S2) or mutant L82A (L82A S2) or empty expression vector (ctrl). Bars show
mean and standard error of the mean (s.e.m.) of six independent β-galactosidase-normalized experiments. (B-E)
Quantitative RT-PCR analyses with immortalized mouse macrophages (B); parental (S2-/-) and stably
STAT2-reconstituted (S2 WT or S2 L82A) human U6A cells (C); and IRF9-deficient U2A (IRF9-/-) and parental
2fTGH cells (WT) (D). Where indicated, cells were pretreated (primed) with IFN-γ (1 U/ml) for 48 h. (E) identical to
(C) except that treatment was with IFN-β. * p < 0.05, ** p < 0.01 and *** p < 0.001. Bars show mean and s.d. of
2–3 independent experiments. See S1 Data for raw data.
doi:10.1371/journal.pbio.2000117.g005
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Il1β, andMarco (Fig 5B; S7A Fig). STAT2-deficient macrophages contained reduced STAT1
protein, which could be normalized to WT levels by IFN-γ priming (S7B Fig), which further
accentuated the enhanced IFN-γ-inducible gene expression of the STAT2-deficient cells (Fig
5B). We expanded the analysis to STAT2-deficient and stably STAT2-reconstituted human
U6A cells, which confirmed significantly enhanced IFN-γ-inducible gene expression in cells
that lacked STAT2 or expressed the STAT1-binding mutant STAT2-L82A compared toWT
STAT2-expressing cells (Fig 5C; S7C Fig). In contrast, a previous study reported that a subset
of IFN-γ target genes including PKR, IFIT3,MXA, and OAS1 was actually induced by semipho-
sphorylated STAT1:STAT2 heterodimers, albeit in association with IRF9 [30]. We used IRF9--
deficient U2A cells, which exhibited slightly reduced STAT1 expression and activation
compared to the parental 2fTGH cells (S7D Fig), yet found that lack of IRF9 resulted in no sig-
nificant difference in the expression of nine genes tested, including the aforementioned subset
of genes after a 4 h IFN-γ exposure (Fig 5D). We additionally tested the serine phosphorylation
of STAT1, which is required for its full-transcriptional activity [3], and found no differences
between theWT and mutant STAT2-reconstituted cells (S7E Fig). We moreover assessed gene
induction in response to type 1 IFN (Fig 5E; S4A Fig). For the 17 genes tested, we found that
transcription was strongly reduced or lost in the absence of STAT2, as expected, but no differ-
ence was seen between cells expressingWT and mutant STAT2, in line with undisturbed type
1 IFN-induced activation and nuclear import of STAT1 and STAT2 (Fig 2A; S4B Fig). Thus,
the loss of constitutive STAT2 binding to STAT1 enhanced gene expression in response to
IFN-γ, but was without overt consequences for type 1 IFN signaling.
STAT2 Modulates Key IFN-γ Effector Functions In Vitro and In Vivo
IFN-γ is a potent cell growth inhibitor and can promote cell death [8]. The influence of STAT2
on different antiproliferative effects of IFN-γwas assessed with immortalizedWT and STAT2-
deficient macrophages. Using Alamar blue reagent, we found that IFN-γ decreased cell viability
of bothWT and mutant macrophages in a concentration-dependentmanner, although the
STAT2-deficient cells were significantlymore sensitive and already showed40% decreased
viability at a low IFN-γ concentration (1 U/ml) that left WT cells unaffected (Fig 6A). Annexin
V staining indicated that this phenomenon entailed apoptosis, as expected.At all IFN-γ con-
centrations tested, the fraction of apoptotic cells was 2–4 times higher for the STAT2-deficient
cells compared toWT (S8A Fig). A particularly noticeable difference betweenWT and
STAT2-deficient macrophages was found when the induction of heterochromatin foci, a
marker for cellular senescence, was assessed (Fig 6B; S8B Fig) [31]. The STAT2-deficient cells
were labelled strongly with antibody against phosphorylated heterochromatin protein
1-gamma (pHP1γ) even at a low IFN-γ concentration (1 U/ml), indicative of extensive chro-
matin reorganization characteristic of cellular senescence.WT cells, in contrast, were only
weakly responsive to IFN-γ, even at the 50-fold increased concentration (S8B Fig). These
experiments documented that lack of STAT2 sensitized cells to multiple growth-inhibitory
effects of IFN-γ.
Type 1 and 2 IFNs up-regulate class I and II antigen presentation pathways, whereby IFN-γ
alone efficiently induces the class II pathway [8]. Prior to treatment with IFN-γ, major histo-
compatibility complex (MHC) class II expression was essentially indistinguishable between
WT and STAT2-deficient immortalizedmacrophages (Fig 6C). Treatment of theWTmacro-
phages with IFN-γ increased the surface expression of MHC class II molecules. Yet, whileWT
cells showed5-fold increase in median fluorescence intensities (MFIs), a15-fold increase
was observedwith the STAT2-deficient macrophages (Fig 6C), even though a very low IFN-γ
concentration was used (0.1 U/ml). Similar, albeit more modest, differences were observed for
STAT2 Regulation of Cytokine Signals
PLOS Biology | DOI:10.1371/journal.pbio.2000117 October 25, 2016 12 / 27
STAT2 Regulation of Cytokine Signals
PLOS Biology | DOI:10.1371/journal.pbio.2000117 October 25, 2016 13 / 27
the induction of MHC class I molecules on human U6A cells (S9A Fig). At the three IFN-γ
concentrations tested, STAT2-deficient and mutant STAT2-L82A-reconstituted cells were
indistinguishable and up-regulatedMHC I significantly better than theWT STAT2-expressing
cells. To assess the consequences of STAT2 deficiency for IFN-γ signaling in vivo, we injected
WT and STAT2 gene-deletedmice on two consecutive days with IFN-γ or PBS (controls) and
collected peritoneal leucocytes 24 h later. Flow cytometry and fluorescent labelling of F4/80
and MHC II molecules were used to identify peritonealmacrophages and to calculate their
MFIs in order to compare the effect of IFN-γ injection on MHC II expression. Based on the
MFI values, IFN-γ injection of WTmice led to about a 3-fold increasedmacrophage MHC II
expression (Fig 6D, left), whereas cells from the STAT2-deficient animals showed 5-fold
increase (Fig 6D, right). In fact, the direct comparison revealed an 8-fold difference between
WT and mutant mice, since in the latter MHC II levels were already twice as high under con-
trol conditions (Fig 6D). We concluded that STAT2-deficient mice were IFN-γ hyper-respon-
sive and displayed STAT1 gain-of-function phenotype regarding antigen presentation
pathways.
The boosting of antimicrobial effectormechanisms is another cardinal IFN-γ-mediated
immune response.We therefore performed infection experiments with the obligate intracellu-
lar protozoan T. gondii, whose elimination requires IFN-γ signaling in humans and mice [32].
T. gondii infection,moreover, does not elicit type 1 IFNs and their potential disease-exacerbat-
ing comorbidities [33]; a phenomenon observed in the course of many infections and an
important consideration, particularly in the context of STAT2 deficiency and hence disrupted
type 1 IFN signaling [34]. At first, WT- and STAT2-deficient mice were injected with IFN-γ or
PBS (controls), before peritoneal macrophages were collected for ex vivo infection experiments
with T. gondii tachyzoites (Fig 6E). IFN-γ injection protected bothWT and mutant mice-
derivedmacrophages from T. gondii-induced cell lysis and concomitant parasite release into
the culture medium, as parasite numbers were about halved (Fig 6E, top panel). Yet, the
STAT2-deficient mice were protected better. Parasite numbers with macrophages from the
PBS-injectedmutant mice already were about 20% lower compared to WT, and this difference
increased to about 50% with the cells from IFN-γ-injectedmice (Fig 6E, top panel). The addi-
tion of IFN-γ to the ex vivo macrophage cultures reduced T. gondii propagation further (Fig
6E, bottom panel), whereby again cells from the STAT2-deficient mice were more resistant to
the parasite. Together, these experiments confirmed that STAT2 deficiencywas associated with
the gain-of-functionphenotype for another key IFN-γ activity in vivo, namely cell-autonomous
Fig 6. STAT2 modulates key IFN-γ effector functions. (A) Viability of immortalized macrophages was
measured by Alamar blue assay of mitochondrial function after 72 h in the presence of IFN-γ. (B) Widefield
microscopy detecting HP1γ (anti-phospho-S83 HP1γ antibody) in immortalized macrophages before (top
four panels) and after (bottom four panels) treatment with IFN-γ. Nuclei were DAPI stained. Scale
bar = 15 μm. (C) Major histocompatibility complex (MHC) II expression on immortalized WT and STAT2-/-
macrophages treated without or with 0.1 U/ml IFN-γ for 72 h was determined by fluorescence-assisted cell
sorting (FACS) using Alexa Fluor 488-conjugated specific and isotype control antibodies. Gating for live cells
was performed using forward and side scatter analysis, and the same gate was used for the histograms in
(C) and (D). MFI, median fluorescence intensity. (D) Same as (C), but using peritoneal leukocytes from mice
injected with PBS or IFN-γ. MHC class II expression (PerCP-conjugated antibody) was analyzed on
macrophages detected by Alexa-Fluor 488-conjugated anti-F4/80 antibody. A representative histogram is
shown and median PerCP fluorescence intensities ± s.d. per cohort (n = animal numbers) are given. (E)
Peritoneal macrophages from PBS or IFN-γ-injected mice were cultured without (top) or with added IFN-γ
(bottom) in duplicates, infected with Toxoplasma gondii, and extracellular parasites were counted at the
indicated time points. Graphs combine the results from five control and eight experimental mice per
genotype, bars show mean and s.d. (F) T. gondii release from infected immortalized macrophages treated
with different IFN-γ concentrations. Results represent two independent experiments, bars show mean and
s.d. (G) Nitric oxide (NO) production by immortalized macrophages determined using Griess reagent in
triplicates after 36 h of the indicated treatments, bars show mean and s.d. See S1 Data for raw data.
doi:10.1371/journal.pbio.2000117.g006
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antiparasitic immunity. To corroborate these findings, we treated immortalizedWT and
STAT2-deficient macrophages for two days with a low (“priming”) IFN-γ concentration (1 U/
ml) to induce anti-T. gondii activity, before infection and continued cultivation without or with
varying IFN-γ concentrations (Fig 6F). In the IFN-γ-untreated cells, parasite release into the
culture medium became apparent 48 h post infection; and over the following three days
extracellular parasite numbers increased about 10-fold, irrespective of STAT2 expression (Fig
6F, upper left panel). At the highest concentration used, IFN-γ protected both cell lines against
parasite propagation almost completely (Fig 6F, upper right panel). The same high level of pro-
tection was conferred on STAT2-deficient cells even at the 50- and 500-fold IFN-γ dilutions
tested (Fig 6F, lower panels). TheWT cells, however, gradually lost the ability to control para-
site growth with decreasing IFN-γ concentrations (lower panels). Additional infection experi-
ments were performedwith STAT2-deficient and reconstituted human U6A cells. While in
this cell line IFN-γ conferred considerably weaker protection against T. gondii, STAT2-defi-
cient and mutant STAT2-L82A reconstituted cells were indistinguishable and suppressed para-
site propagation significantly better thanWT STAT2-expressing cells, in line with a
suppressive effect of STAT2 on STAT1 and IFN-γ (S9B Fig). Finally, the production of cyto-
toxic nitric oxide (NO) was assessed by treating cells either with IFN-γ or bacterial lipopolysac-
charide (LPS) alone or combined, which resulted in synergistic NO up-regulation both inWT
and STAT2-deficient macrophages (Fig 6G) [35]. However, the STAT2-deficient cells released
4–5 times more NO thanWT at both IFN-γ concentrations tested (Fig 6G). Taken together,
these experiments demonstrated that STAT2 dampens key immunomodulatory activities of
IFN-γ both in vitro and in living mice.
STAT2 Balances the Contributions of STAT1 and STAT3 to IL-27
Transcription Output
IL-27 signals via the concomitant activation of both STAT1 and STAT3, but only STAT1
nuclear translocation was inhibited by STAT2 (Fig 3B). To examine how this affected gene
induction, we selected several genes whose expression is known to depend on STAT1 or
STAT3, respectively, and compared their induction using IL-27 in STAT2-deficient U6A cells
and U6A cells reconstituted withWT STAT2 or the L82Amutant. Ten STAT1-regulated genes
were selected based on their responsiveness to IFN-γ [21], while five STAT3 targets were cho-
sen based on their IL-6 responsiveness [36]. Dependency on STAT1 was confirmed by the lack
of expression in IL-27-treated U3A cells (Fig 7A), a STAT1-deficient human fibrosarcoma line
[28]. The five selected STAT1-independent genes tested (JUNB, BCL6, PIM1, BIRC5, and
MCL1), in contrast, were expressed equally well in WT cells and the STAT1-deficient U3A
cells (Fig 7B), presumably due to the activation of STAT3. There was, moreover, no significant
influence of STAT2 on the IL-27-induced expression of this set of genes (Fig 7B). Contrary, of
the ten STAT1-dependent genes tested, five (IRF1,GBP1, CXCl9, CXCl10, ICAM1) showed sig-
nificantly increased gene expression in response to IL-27 both in the absence of STAT2 and in
the presence of the L82Amutant compared toWT STAT2 (Fig 7A), thus resembling the situa-
tion with IFN-γ (Fig 5B and 5C). Three additional genes likewise showed increased IL-27
responsiveness in the absence of STAT2, albeit the differences did not reach significance;while
the remaining two STAT1-dependent genes tested,MXA and OAS1, were unresponsive to IL-
27. Although the reason for their unresponsiveness is presently unknown, a contribution of
STAT2 was ruled out, as they did not gain responsiveness in the absence of STAT2 (Fig 7A).
We additionally explored a possible alternative explanation for the differential IL-27 respon-
siveness of genes in the cells expressing WT or mutant STAT2, namely differences in STAT1
tyrosine and serine phosphorylation, but found comparable phosphorylation levels in both cell
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types using western blotting (Fig 3A, S7E Fig). Collectively, these data indicate that STAT2 is a
general STAT1 inhibitor whose activities include balancing the contributions of STAT1 and
STAT3 to the transcription output of IL-27.
Discussion
STAT2 is a founding member of the STAT family of transcription factors [37]. It is considered
a STAT protein with an uncharacteristically narrow activity profile, namely as a facilitator
solely of type 1/3 IFN signaling [13]. Here, we identify STAT2 as a pervasive cytokine regulator
due to its inhibition of STAT1 in multiple signaling pathways. The results represent a substan-
tial expansion of known STAT2 biological roles, beyond type 1/3 IFN signaling, and firmly in
the IFN-γ, IL-27, and IL-6 pathways. However, it is the unphosphorylated STAT2 that func-
tions as a STAT1 inhibitor. To our knowledge, this is the first example of a latent STAT protein
interfering with the cytokine-inducible activities of another, namely STAT1. STAT1 is tradi-
tionally associated with IFN-γ signaling, but functions downstream of many additional cyto-
kine receptors often in conjunction with STAT3. Examples include IL-6, IL-21, and IL-27, the
latter of which activates STAT1 and STAT3 strongly and with comparable potency in many
cell types. Our analysis of IL-27 signaling has only covered two classes of genes. A first class
comprises genes that are unresponsive in the absence of STAT1, i.e., whose expression is
Fig 7. STAT2 shifts the transcriptional output of IL-27 from STAT1 to STAT3. (A, B) Gene expression
analyses using quantitative reverse transcription polymerase chain reaction (qRT-PCR) with human U3A (S1-/-)
cells and parental (S2-/-) and stably STAT2-reconstituted (S2 WT or S2 L82A) human U6A cells treated for 4 h
with 100 ng/ml IL-27. * p < 0.05, bars show mean and s.d. of 2–3 independent experiments. See S1 Data for raw
data.
doi:10.1371/journal.pbio.2000117.g007
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regulated solely by STAT1. For many of these, STAT2-mediated reduction in nuclear STAT1
translates directly in diminished transcription, similar to the effects on IFN-γ. In contrast,
STAT1 does not appear to make a contribution at all for a second class of genes examined, i.e.,
genes that are induced similarly well in the absence and presence of STAT1. In agreement with
STAT2 inhibition being specific for STAT1, but not STAT3, their expression is insensitive to
the presence of STAT2. The situation likely is more complex for a sizable third class of genes
not examined here where expression is coregulated by STAT1 and STAT3 or other STATs
[12]. For these genes, STAT2-mediated inhibition of STAT1 is expected to shift promoter
occupancy away from STAT1 to STAT3 and possibly other STATs with difficult-to-predict
consequences for the IL-27 transcriptome.While this and other questions await clarification,
the already acquired data identify STAT2 as a crucial component of a filteringmechanism for
IL-27 and other cytokines whose biological outcomes critically depend upon balancing the
transcriptional potency of STAT1 and competing STAT proteins [12,38].
Our results showed that only STAT1 molecules free of STAT2 are available for mediating
cytokine functions, such that the modulation of the STAT1:STAT2 protein ratio provides a
mechanism for cells to fine tune their cytokine responses and possibly contributing to cell type
specificity if the distinctions become permanent. Our limited survey of cell lines has demon-
strated that STAT1 is present in excess over STAT2, and that the STAT1:STAT2 ratio of these
IFN-stimulated genes was increased further by treatment with IFNs. In this manner, the expo-
sure of cells to IFNs contributes to their increased IFN-γ responsiveness and will tweak the bio-
logical activities of multiple additional cytokines towards the STAT1 component in their
transcription output. The identification of the STAT1:STAT2 protein ratio as a key determi-
nant for the functioning of STAT1 moreover invalidates the assumption that STAT1 tyrosine
phosphorylation can be equated with its biological activity. This is an important consideration,
as cytokine responses are dynamic and depend on the strength of the incoming stimulus. IFN-
γ-mediated antibacterial immunity, for example, can be viewed as a continuous quantitative
trait, where cell activation correlates with outcome of infection [39]. We therefore suggest tak-
ing STAT2 protein expression into account when assessing STAT1 bioactivity, including as
predictor of prognosis in cancer and disease development [40]. Heterodimers of STAT1 and
STAT2 are well known to bind the transcription factor IRF9. This can occur both before and
after their type 1 IFN-induced phosphorylation, resulting in trimeric transcription inducers
termedU-ISGF3 and ISGF3, respectively [3,41]. A similar interaction between IRF9 and semi-
phosphorylated STAT1:STAT2 heterodimers was previously shown to promote IFN-γ signal-
ing [30]. In light of our findings, this suggests that IRF9 may alleviate the inhibitory activity of
such heterodimers. Our assessment of immediate early and hence direct transcription
responses, however, did not provide evidence for this, although we cannot formally rule out
that IRF9 contributes to late transcriptional responses involving semiphosphorylated STAT1:
STAT2 heterodimers, possibly by an indirect mechanism. Irrespective, semiphosphorylated
dimers of both STAT1 and STAT3 resulting from experimental and clinical tyrosine-phos-
phorylationmutations are associated with defective nuclear import and dominant-negative
consequences for cytokine signaling [42–44]. This includes the demonstration that nonpho-
sphorylatable STAT1 inhibits the nuclear import of activated STAT2 as well as gene induction
in response to type 1 IFNs [27], making this artificial system the exact complement of what we
find in the natural setting with IFN-γ.
The loss of STAT2 can be described as a gain-of-function phenotype for STAT1, of which
unrestrained IFN-γ activity is an important consequence, as shown here. However, previous
studies with STAT2-deficient patients and mice failed to reveal this aspect. This is probably
due to at least three reasons: firstly, although increased IFN-γ responses such as gene induction
were noticed occasionally [14], these observationswere not pursued as the focus of those
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studies was on type 1 IFN rather than IFN-γ. Secondly, those studies concentrated on the tyro-
sine phosphorylation of STAT1, which not only is unaffected by STAT2 but moreover an insuf-
ficient measure for the biological activity of STAT1 and IFN-γ, as we have discussed above.
Thirdly, and more importantly, STAT1 protein concentrations are reduced by 50%–80% in
STAT2-deficient cells from both patients and mice compared toWT [14,15]. This phenome-
non, which is probably caused by the disruption of a STAT2-dependent IFN-β feedback loop
[45], may abolish the STAT1 gain-of-function phenotype associated with STAT2 deficiency.
The prolonged exposure to IFN-γ, however, for example during chronic or acute inflammation,
can increase STAT1 protein toWT levels such that the gain-of-function phenotype can come
into effect and may manifest as disease exacerbation such as seen for LPS-inducedmurine sep-
sis [17]. In conjunction with the considerable functional overlap of type 1 and 2 IFNs, on the
other hand, compensatory outcomes can ensue, as suggested by the capacity of IFN-γ to induce
an antiviral state in the absence of type 1 IFN signaling [46] and contribute to the unexpectedly
narrow role for STAT2 deficiency in human antiviral immunity [15]. Further work is required
to verify these possibilities, which will be facilitated by the STAT1-binding mutant described in
this work, as it allows the dissociation of STAT2’s effects on type 1 and type 2 IFN. As such, N
domain-mediated STAT2 heterodimerizationmoreover is a potentially attractive target for
small molecule-basedenhancement of endogenous IFN-γ activity.
The identification of STAT2 as another perpetual STAT1 inhibitor, in addition to SUMO
[47], underscores the importance of constitutive signal-dampeningmechanisms in STAT1
biology to avoid disease associated with STAT1 hyperactivity [48,49]. However, STAT2 does
not target the activation of STAT1, but the subsequent step, its nuclear import. This is a new
cytokinemodulationmechanism for a STAT protein, but one reminiscent of viral IFN evasion
strategies, e.g., by Ebola virus VP24 protein [50]. The results moreover provide an alternative
interpretation for the functioning of the STAT1β splice variant, which in lacking a transactiva-
tion domain is generally considered a STAT1 antagonist with an unclear biological role [51]. In
light of the findings reported here, it can be seen as a STAT2 quencher–through its N domain–
and hence rather as a promoter of cytokines that signal via STAT1. Finally, the constitutive
interactions between STAT2 and STAT1 are exceedingly tight, yet highly vulnerable to muta-
tion of either STAT1 (F77A) or STAT2 (L82A), suggesting strong evolutionary pressure in
favor of heterodimerization. Counterintuitively, heterodimerizationwas dispensable for the
assembly and the functioning of canonical ISGF3 (this work and [21]). It thus appears that the
binding of STAT2 to STAT1 exists not because it supports the cytokine inducible activities of
STAT2, but because it attenuates those of STAT1.
Materials and Methods
Ethics Statement
Procedures were undertaken in accordance with the UK Animals Scientific Procedures Act
under project license 40/3601.
IFN Treatment of Mice
C57BL6/6J mice were purchased from Charles River UK; B6.129-Stat2tm1Shnd/J (Stat2-/-)
mice [14] were obtained from Dr. Thomas Decker, Universität Wien, with the permission of
Dr. Christian Schindler, Columbia University. Eight to ten wk-oldmales with a mean body
weight of 25 g (21 g–29 g) were injected with 5 μg of carrier-freemouse IFN-γ (2.0–10.0 x 106
units/mg, Biolegend #575308) on two consecutive days. On day three the mice, being in appar-
ently healthy state, were sacrificedby cervical dislocation followed by peritoneal lavage [52]
and tissue collection. Lavage samples for FACS analysis were fixed for 30 min in 4% PFA in
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PBS at 4°C prior to antibody staining. All mice that entered the study are included in the final
analysis described in the figures with the exception of one: A STAT2 -/- mouse, injectedwith
IFN-γ, was found to have an exceptionally highMHC class II expression on peritoneal macro-
phages (MFI 33.6). Whilst this followed the general trend of macrophages from STAT2 -/- ani-
mals having greater MHC class II up-regulation in response to IFN-γ, this animal was treated
as an outlier and subsequently not included in calculating the average median intensity for the
relevant cohort.
Cell Culture and Transfections
Immortalized bonemarrow-derivedmacrophages fromWT and STAT2 -/- mice were
obtained from authors of [17] and grown as described.U6A cells were stably reconstituted
with YFP-tagged human STAT2 or STAT2-L82A and isolated by FACS. U2A, U3A, and U6A
cell lines were obtained from G. Stark [53]. See S1 Text for additional details.
Cytokines and Other Treatments
Human (#407306) and mouse (#407320) IFN-γ, human IL-6 (#407652) were purchased from
Merck Millipore, human IFN-β (#11415–1) was from PBL Assay Science.Human IL-6Rα was
from R&D Systems (#227-58-025), human IL-27 from Peprotech (#200–38). Other treatments
used in this work include LPS (#L7895, Sigma) and ratjadone (#553590, Merck Millipore).
Unless stated otherwise, IFN treatment was for one hour with 50 U/ml IFN-γ or 500 U/ml
IFN-β in growth medium. Similarly, unless stated otherwise, IL-27 treatment was performed
for 40 min at a concentration of 100 ng/ml. IL-6/IL-6R cotreatments also lasted for 40 min at
concentrations of 200 and 250 ng/ml, respectively.
Experiments with T. gondii
T. gondii, provided by Dr. Gereon Schares, were grown and purified as previously described
[54]. Briefly, tachyzoites were maintained in vitro by serial passage throughMadin-Darby
Canine Kidney (MDCK) cells in DMEM supplemented with 5% FBS, 2 mM glutamine, and 1%
(v/v) antibiotic-antimycotic solution (Gibco). Immediately prior to infection, tachyzoites were
purified from their feeder cell cultures by passage through PD-10 desalting columns. The puri-
fied tachyzoites were centrifuged at 1,000 × g, and the parasite pellet was suspended in fresh
culture medium. Parasites were counted with an improved Neubauer hemocytometer. Perito-
neal macrophages for ex vivo T. gondii experiments were isolated as previously described [55].
Briefly, lavage cells were plated onto Poly-L-lysine coated glass coverslips and incubated for 3 h
in DMEM supplemented with antibiotics and 10% FBS (growth medium). Nonadherent cells
were removed by rigorous washes with PBS and the remaining adherent macrophages were fed
fresh growth medium. Lavage cells were plated at a density of 1 x 105 cells per well with inten-
tion to obtain a density of 5 x 104 peritoneal macrophages per well. Actual densities achieved
were determined for each mouse by counting an additional coverslip used subsequently to cal-
culate MOI. Immortalizedmacrophages and U6A cells were plated on poly-L-lysine-coated
24-well culture plates (Nunc) at a density of 5 x 104 cells per well and incubated in 0.5 ml
growth medium for 15 h. Cells were left untreated or treated for 48 h with IFN-γ at the indi-
cated concentrations, before infection for 5 h with tachyzoites at a MOI of 3. Unattached
parasites were washed away with PBS, and cells were fed fresh growth medium containing the
same IFN-γ concentration as before. Extracellular parasites were counted using 100 μl medium
samples, followed by replacement with the appropriate culture medium such that IFN-γ con-
centrations were maintained. Data from at least two biological replicates were evaluated, and
averages were calculated.
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NO Assay and Alamar Blue Assay
Determination of NO and cell viability, using Griess reagent (Promega) and Alamar blue assay
(Bio-Rad), respectively, was done as described by the manufacturers. See S1 Text for additional
details.
FACS to Detect MHC Expression and Cell Death
For MHC expression analyses, cells were grown for 72 h in the absence or presence of IFN-γ as
indicated. Apoptosis analyses were done with cells left untreated or treated for 48 h with IFN-γ
as indicated. Following treatment, cells were detached and suspended in ice-cold PBS contain-
ing 0.2% heat-inactivatedmouse serum (MS). After two washes in this buffer by centrifugation
at 300 x g for 5 min each, cell suspensions (2.5 x 105 cells in 100 μl) were incubated for 20
min at RT with 4 μg/ml Alexa Fluor-488 rat antimouse IA/I-E (#107615, Biolegend) or 4 μg/ml
Alexa Fluor-488 rat IgG2b, κ isotype control (#400625, Biolegend) for the detection of MHC
class II expression on mouse macrophages. MHC class I on human U6A cell lines was detected
by the same procedure using 3.2 μg/ml APC-conjugated anti-human HLA-A,B,C (#311409,
Biolegend) or APC-conjugated mouse IgG2a, κ isotype control (#400219, Biolegend). For anal-
ysis of peritoneal lavage samples, PFA-fixed cell suspensions were incubated for at least 30 min
in PBS containing 0.2% heat-inactivatedMS prior to 20 min incubation at RT with 5 μg/ml
Alexa Fluor-488 anti-mouse F4/80 (#123119, Biolegend), 2 μg/ml PE/Cy7 anti-mouse CD3
(#100219, Biolegend), 2 μg/ml PE anti-mouse CD45R/B220 (#103207, Biolegend) and 4 μg/ml
PerCP anti-mouse IA/I-E (#107623, Biolegend). Isotype controls were carried out using identi-
cal concentrations of Alexa Fluor-488 rat IgG2a, κ (#400525, Biolegend), PE/Cy7 IgG2b, κ
(#400617, Biolegend), PE rat IgG2a, κ (#400507, Biolegend) and PerCP IgG2b, κ (#400629,
Biolegend) control antibodies. F4/80+ cells were identified as peritonealmacrophages and
their MHC class II expression was subsequently analyzed. Apoptosis and necrosis were ana-
lyzed by simultaneous detection of cell surface annexin V and propidium iodide as described
by the manufacturer (#640914, Biolegend), whereby Biolegend’s cell staining buffer was
replaced with MS. Immediately before FACS using FC500 (Beckman-Coulter)or LSRII flow
cytometers (Beckman-Coulter), cell suspensions were passed once through a 20G needle on a 1
ml syringe. FACS data were processed using Kaluza analysis software (BeckmanCoulter, ver-
sion 1.3).
Plasmids and Molecular Cloning
See S1 Text for additional details.
Gene Expression Analyses
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was done as
described [21]. See S1 Text for additional details.
Fluorescence Microscopy
Endogenous proteins were detected after fixation of cells for 15 min in ice-coldmethanol and
blocking for 1 h in 20% (v/v) FBS/PBS prior to 15 h incubation at 4°C with primary antibodies.
A Zeiss Axioplan 2 microscope and AxioVision 4.7 software (Zeiss) were used for widefield
immunofluorescence imaging; deconvolution microscopy was done with a DeltaVision Elite
microscope (GE Lifesciences) and Resolve 3D software (Softworx). Line scan analysis of STAT
protein subcellular distribution was performed using ImageJ. Within each cell the YFP, CFP,
or Cy3 fluorescence intensity within the cytoplasm or nucleus was measured across separate
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10.6 μm line scans. The MeFI across the cytoplasmic line scan was divided by that of the
nucleus; producing a ratio of cytoplasmic:nuclear fluorescence intensity for the cell. Data
shown represent at least 25 cells per condition. See S1 Text for additional details.
Quantitative Western Blotting
Whole cell extractions, SDS-PAGE, and quantitative western blotting were as described [56].
Results combine or are representative of at least two independent experiments. See S1 Text for
additional details.
Immunoprecipitation and EMSA
For STAT1 precipitation experiments, HEK 293T cells were cotransfectedwith expression vec-
tors for STAT2 and FLAG-tagged STAT1 variant proteins, or pCMV-FLAG-N expression vec-
tor as control. For importin-α5 precipitations, FLAG-tagged importin-α5 [50] and vector
encoding YFP-tagged STAT1 or STAT1-Y701F was cotransfected, with pEGFP-N1 used as
control. The cells were treated without or with IFN-β for 1 h before extraction. Extracts were
incubated with anti-FLAGM2magnetic beads (Sigma). For EMSA, cell extracts were normal-
ized for Tyr701-phosphorylated STAT1 and incubated with radiolabeledGAS (M67) or ISRE
(ISG15) probes as described [21]. See S1 Text for additional details.
Protein Preparation and Analytical Ultracentrifugation
STAT N domain expression in insect cells, affinity-purification (Strep-Tag), and sedimentation
analyses were as described [22]. Sedimentation equilibrium data were obtained with STAT1 N
domain and mEGFP-tagged STAT2 N domain at final equimolar concentrations of 2.5, 10,
and 40 μM. See S1 Text for additional details.
Statistical Analyses and Software
Statistical significancewas calculated by Student’s t test ( denotes p< 0.05;  p< 0.01; and
 p< 0.001; n. s. denotes p> 0.05) performed using GraphPad Prism 5.03 (GraphPad).
Quantitative western blot analysis was performed using Image Studio Lite (Li-Cor, version
3.1).
Supporting Information
S1 Fig. STAT2 overexpression does not trigger cytoplasmic redistribution of STAT3 and
STAT4. HeLa cells transiently overexpressing YFP-tagged STAT2 were fixed and stained with
antibodies detecting endogenous STAT3 and STAT4 and a Cy3-coupled secondary antibody as
indicated. Nuclei were DAPI-stained. Scale bar = 15 μm.
(TIF)
S2 Fig. NES-mediatednuclear export of STAT2 drives the accumulation of STAT1 in the
cytoplasm. (A) STAT1-CFP and YFP-tagged C-terminally-deletedSTAT2 (STAT2-ΔC) were
expressed in HeLa cells and their subcellular localizationwas observedby deconvolution
microscopy. Scale bar = 15 μm. (B)HeLa cells co-expressing STAT1-CFP and STAT2-YFP
were treated with 10 ng/ml ratjadone for 6 h before fixation and viewing as in (A). Scale
bar = 15 μm.
(TIF)
S3 Fig. STAT2 singlemutant L82A and double mutant LL81,82AA are functionally identi-
cal. STAT1-CFP and the indicated YFP-tagged STAT2 wild type or mutant variants were co-
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expressed in HeLa cells and their subcellular localizationwas observedby deconvolution
microscopy. Scale bar = 10 μm.
(TIF)
S4 Fig. Abrogated heterodimerizationbetween STAT1 and STAT2 does not affect their
IFN-β-inducednuclear import and gene induction. (A)Gene induction determined by
qRT-PCR with parental (S2-/-) and stably STAT2-reconstituted (S2WT or S2 L82A) human
U6A cells after treatment with IFN-β (500 U/ml) for 4 h. (B) STAT1-CFP and YFP-tagged
wild type (top panels) or L82Amutated STAT2 (bottom panels) were co-expressed in HeLa
cells and their subcellular localization was observedby deconvolution microscopy after 1 h in
the presence of IFN-β. Note assembly and co-localization of STAT1 andWT STAT2, but not
the mutant STAT2, in nuclear bodies, presumably paracrystals. Such structures and their loss
upon the disruption of N domain-mediated (antiparallel) homodimerization have been dem-
onstrated for WT STAT1 and mutant F77A [57]. Scale bar = 10 μm. See S1 Data for raw data.
(TIF)
S5 Fig. Effects of WT andmutant STAT2 on IFN-mediated STAT1 activation. Parental
(S2-/-) and stably STAT2-reconstituted (S2WT or S2 L82A) human U6A cells were left
untreated (-) or treated (+) with IFN as indicated.Western blotting results with whole cell
extracts are shown using antibodies (denoted by α) detecting phospho-Y701 STAT1 (pS1),
STAT1 (S1), phospho-Y690 STAT2 (pS2), STAT2 (S2), and β-actin. kD, kilo Dalton.
(TIF)
S6 Fig. Determination of the relative binding affinities of STAT1 and STAT2 antibodies.
(A)Whole cell extracts of HEK 293T cells co-expressing STAT1-YFP and STAT2-YFP were
serially diluted as indicated, resolved by SDS-PAGE and probed with anti-GFP antibody (lanes
1–6) and re-probed with either anti-STAT1 (lanes 7–12, bottom) or anti-STAT2 (lanes 7–12,
top). GFP expression (lane 1) was used as antibody control. (B) The bar graph combines the
results of (A) with a technical replicate. Given are the mean numerical values of the STA-
T2-YFP/STAT1-YFP signal ratios determined using anti-GFP (value A; white bars) or the
respective anti-STAT1 and anti-STAT2 antibodies (value B; black bars). [B/A] was determined
to be 5.7 and is the fold-difference in binding affinity between anti-STAT2 and anti-STAT1.
Bars show mean and s.d. See S1 Data for raw data.
(TIF)
S7 Fig. Influence of L82Amutated STAT2 and increasedSTAT1 concentration relative to
STAT2 on IFN-γ induced gene induction; assessment of IRF9 expression on the IFN-medi-
ated activation of STAT1 and STAT2; and assessment of cytokine-inducedSTAT1 serine
727 phosphorylation. (A)Gene induction determined by qRT-PCR with immortalizedmacro-
phages following treatment with IFN-γ (50 U/ml) for 4 h. Where indicated, cells were pre-
treated (primed) with 1 U/ml IFN-γ for 48 h. (B)Western blotting experiments showing the
effect of 48 h treatment with the indicated concentrations of IFN-γ on STAT1 (αS1) and
STAT2 (αS2) expression in macrophages. (C) Same as in (A) but with parental (S2-/-) and sta-
bly STAT2-reconstituted (S2WT or S2 L82A) human U6A cells.  p< 0.05,  p< 0.01.
RT-PCR results are representative of three independent experiments; bars show mean and s.d.
(D)Western blotting experiments investigating the effect of IRF9 expression on IFN-induced
tyrosine phosphorylation of STAT1 and STAT2. Parental 2fTGH cells (WT) and IRF9-defi-
cient U2A cells (IRF9-/-) were left untreated or treated for 1 h with IFN-γ or IFN-β as indi-
cated. Results with whole cell extracts are shown using antibodies (denoted by α) detecting
phospho-Y701 STAT1 (pS1), STAT1 (S1), phospho-Y690 STAT2 (pS2), STAT2 (S2), IRF9 and
β-actin. kD, kilo Dalton. (E)Western blotting experiments investigating the effect of
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STAT2-L82A on STAT1 serine 727 phosphorylation. U6A cells stably expressing STAT2 or
STAT2-L82A were left untreated or treated with IFN-γ (50 U/ml); IL-27 (100 ng/ml); or co-
treated with Il-6 (200 ng/ml) and soluble IL-6R (250 ng/ml) for 40 minutes. Results with whole
cell extracts are shown using antibodies (denoted by α) detecting phospho-S727 STAT1
(pS1S727), STAT1 (S1) and β-actin. kD, kilo Dalton. See S1 Data for raw data.
(TIF)
S8 Fig. STAT2-deficient cells are sensitized to anti-proliferative effects of IFN-γ. (A) Flow
cytometric analysis of cell death inWT (top) and STAT2-deficient (bottom) macrophage cell
lines. Cells were left untreated or treated with increasing concentrations of IFN-γ for 48 h,
before analysis of apoptosis and necrosis by simultaneous detection of cell surface annexin V
and DNA binding of propidium iodide. (B)Widefield immunofluorescence microscopy
images showing labelling with anti-pHP1γ antibody (red) in immortalizedWT and STAT2-de-
ficient macrophages left untreated or treated with 10 (top) and 50 (bottom) U/ml IFN-γ for 72
h; nuclei are blue. Scale bar = 15 μm.
(TIF)
S9 Fig. STAT2 regulates cardinal IFN-γ responses. (A) Representative histograms of MHC
class I expression on U6A (middle) and WT STAT2- (left) and STAT2-L82A-reconstituted
(right) cells. Cells were left untreated or treated for 72 h with 1 (top), 5 (middle) and 50 (bot-
tom) U/ml IFN-γ. Dashed lines denote mode intensity values for untreated and IFN-treated
cells, respectively. MFI, median fluorescence intensities. (B) Influence of IFN-γ on T. gondii
propagation in parental and stably STAT2-reconstituted human U6A cell. After infection
(t = 0), extracellular parasites were counted at the indicated time points using a Neubauer
chamber. Results are representative of two independent experiments carried out in duplicates,
bars show mean and s.d. See S1 Data for raw data.
(TIF)
S1 Text. SupplementalMaterial andMethods, References.
(DOCX)
S1 Data. Underlying data and quantitative observationspresented in figures.
(XLSX)
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